Trial · NCT05557656
A Real World Study of Regogfinib in HCC
NCT05557656, Unknown, Zhongda Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real World Study of Regogfinib in HCC. Trials, record NCT05557656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05557656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real World Study of Regogfinib in HCC
- NCT number
- NCT05557656
- Status
- Unknown
- Enrollment
- 800 participants, estimated
- Lead sponsor
- Zhongda Hospital
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Regorafenib 40 MG
- First posted
- 2022-09-28
- Last updated
- 2022-12-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | Time from the start of regorafenib treatment to the date of death from any cause or last follow-up，whichever came first, assessed up to 60 months | Overall survival was defined as the time from the start of regorafenib treatment to the date of death from any cause or last follow-up |
| Secondary | Progression-free survival (PFS) | Time from the start of regorafenib treatment to the date of the first documentation of disease progression or death from any cause，whichever came first, assessed up to 60 months. | Progression-free survival was defined as the time from the start of regorafenib treatment to the date of the first documentation of disease progression or death from any cause. |
| Secondary | Time to progression (TTP) | Time from the start of regorafenib treatment to the date of the first documentation of disease progression，whichever came first, assessed up to 60 months | Time to progression was defined as the time from the start of regorafenib treatment to the date of the first documentation of disease progression. |
| Secondary | Objective response rate (ORR) | Time from the start of regorafenib treatment to the date of the first documentation of objective response，assessed up to 60 months. | Objective response rate was defined as the proportion of patients with CR or PR in the overall population |
| Secondary | Disease control rate (DCR) | Time from the start of regorafenib treatment to the date of the first documentation of CR or PR or stable，assessed up to 60 months. | Disease control rate was defined as the proportion of patients with CR or PR or stable disease (SD) in the overall population |
| Secondary | Adverse events (AEs) | Time from the start of regorafenib treatment to the date of death or last follow up，whichever came first,assessed up to 60 months. | adverse events (AEs) (including type and grade according to CTCAE 5.0) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05557656
GET https://conductscience.org/api/trials/v1/NCT05557656/registered